US 11,786,687 B2
Cannula for minimizing dilution of dosing during nitric oxide delivery
Craig Flanagan, Belmar, NJ (US); Simon Freed, Providence, RI (US); John Klaus, Cottage Grove, WI (US); Thomas Kohlmann, McFarland, WI (US); Martin D. Meglasson, Bloomsbury, NJ (US); Manesh Naidu, Randolph, NJ (US); and Parag Shah, Morristown, NJ (US)
Assigned to Mallinckrodt Hospital Products IP Limited, Dublin (IE)
Filed by Mallinckrodt Hospital Products IP Limited, Mulhuddart (IE)
Filed on Feb. 10, 2020, as Appl. No. 16/785,978.
Application 16/785,978 is a continuation of application No. 15/412,348, filed on Jan. 23, 2017, granted, now 10,556,082.
Application 15/412,348 is a continuation of application No. 14/312,003, filed on Jun. 23, 2014, granted, now 9,550,039, issued on Jan. 24, 2017.
Application 14/312,003 is a continuation of application No. 14/096,629, filed on Dec. 4, 2013, granted, now 8,770,199, issued on Jul. 8, 2014.
Claims priority of provisional application 61/856,367, filed on Jul. 19, 2013.
Claims priority of provisional application 61/784,238, filed on Mar. 14, 2013.
Claims priority of provisional application 61/733,134, filed on Dec. 4, 2012.
Prior Publication US 2020/0171259 A1, Jun. 4, 2020
Int. Cl. A61M 16/06 (2006.01); A61M 16/10 (2006.01); A61M 16/20 (2006.01); A61M 16/12 (2006.01); A61M 16/08 (2006.01); A61M 16/00 (2006.01)
CPC A61M 16/0677 (2014.02) [A61M 16/009 (2013.01); A61M 16/0666 (2013.01); A61M 16/0672 (2014.02); A61M 16/0875 (2013.01); A61M 16/10 (2013.01); A61M 16/104 (2013.01); A61M 16/1005 (2014.02); A61M 16/122 (2014.02); A61M 16/125 (2014.02); A61M 16/204 (2014.02); A61M 16/208 (2013.01); A61M 16/101 (2014.02); A61M 2016/0021 (2013.01); A61M 2016/0027 (2013.01); A61M 2202/0208 (2013.01); A61M 2202/0266 (2013.01); A61M 2202/0275 (2013.01); A61M 2202/0283 (2013.01); A61M 2205/0216 (2013.01); A61M 2205/3303 (2013.01); A61M 2205/3331 (2013.01); A61M 2205/75 (2013.01); A61M 2210/0618 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A nasal cannula for therapeutic gas delivered to a patient in need thereof, comprising:
a first lumen, a second lumen, and a third lumen;
wherein the first lumen is a first therapeutic gas lumen for delivering a first therapeutic gas to a patient in need thereof,
wherein the second lumen is a triggering lumen, and
wherein the third lumen is a second therapeutic gas lumen for delivering a second therapeutic gas to the patient; and
a cannula nosepiece allowing separate flow paths to the patient for at least one of (i) the first therapeutic gas lumen, (ii) the triggering lumen, and (iii) the second therapeutic gas lumen,
wherein the first therapeutic gas lumen comprises a material selected from the group consisting of polyvinylidene chloride (PVDC) and ethylene vinyl alcohol (EVOH),
wherein the first therapeutic gas lumen comprises a co-extrusion of polyvinyl chloride (PVC) and EVOH or a co-extrusion of PVC and PVDC.